The University College London Hospitals NHS Trust (UCLH) said that the researchers in the Storm Chase study believe a Long Acting AntiBody (LAAB) known as AZD7442, developed by AstraZeneca, may offer immediate and long-term protection to people who have been recently exposed to the SARS-CoV-2 coronavirus and prevent them developing Covid-19.from World News Headlines, Latest International News, World Breaking News - Times of India https://ift.tt/38C7pyP
0 Comments